Percutaneous Pulmonary Valve Implantation Present Status and Evolving Future

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

卷:66

Review

Ansari, Mohammad M.¹  Cardoso, Rhanderson²  Garcia, Daniel²  Sandhu, Satinder³  Horlick, Eric⁴  Brinster, Derek⁵  Martucci, Giuseppe⁶  Piazza, Nicolo⁶ 

[1] Michigan State Univ, Metro Hlth Hosp, Metro Heart & Vasc Inst, Wyoming, MI USA

[2] Univ Miami, Jackson Mem Hosp, Dept Med, Div Cardiol, Miami, FL 33136 USA

[3] Univ Miami, Jackson Mem Hosp, Dept Med, Div Pediat Cardiol, Miami, FL 33136 USA

[4] Toronto Gen Hosp, Dept Med, Peter Munk Cardiac Ctr, Div Cardiol, Toronto, ON M5G 1L7, Canada

[5] Lenox Hill Heart & Vasc Inst, Dept Cardiothorac Surg, New York, NY USA

[6] McGill Univ, Ctr Hlth, Dept Med, Div Cardiol, Montreal, PQ, Canada

关键词: congenital heart disease;    outcome assessment (health care);    pulmonary regurgitation;    right ventricular outflow tract dysfunction;    transcatheter pulmonary valve;   

DOI  :  10.1016/j.jacc.2015.09.055

来源: Elsevier

【 摘 要 】

Due to recurrent right ventricular outflow tract (RVOT) dysfunction, patients with complex congenital heart disease of the RVOT traditionally require multiple surgical interventions during their lifetimes. Percutaneous pulmonary valve implantation (PPVI) has been developed as a nonsurgical alternative for the treatment of right ventricular to pulmonary artery stenosis or pulmonary regurgitation. PPVI has been shown to be a safe and effective procedure in patients with dysfunctional surgical RVOT conduits. In this population, PPVI has the potential to improve symptoms, functional capacity, and biventricular hemodynamics. However, limitations to the anatomical substrate and size of the RVOT currently restrict PPVI eligibility to less than one-quarter of patients with RVOT dysfunction. The current review discusses contemporary practices in PPVI, evidence supporting the procedure, and future technologies and developments in the field. (C) 2015 by the American College of Cardiology Foundation.

【 授权许可】

Free